Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates a positive sentiment due to a 15% revenue increase and improved gross margin from 60% to 65%. Despite a net loss, the reduction from $1.5 million to $1.2 million signals progress. The company's focus on high-growth segments and strategic initiatives further supports a positive outlook. However, the absence of guidance and increased operating expenses slightly temper enthusiasm. Overall, the financial performance and strategic focus suggest a positive stock price movement in the short term.
Revenue Nuwellis reported revenue of $2.5 million for Q1 2026, representing a 15% increase year-over-year. This growth was attributed to higher sales volume and increased adoption of the company's products.
Gross Margin The gross margin improved to 65% in Q1 2026, up from 60% in the same period last year. The improvement was driven by better cost management and operational efficiencies.
Operating Expenses Operating expenses were $3.2 million in Q1 2026, a 10% increase compared to the prior year. The rise was due to higher investments in research and development and marketing initiatives.
Net Loss The net loss for Q1 2026 was $1.2 million, compared to a net loss of $1.5 million in Q1 2025. The reduction in net loss was primarily due to increased revenue and improved gross margin.
The selected topic was not discussed during the call.
Forward-looking statements: The company acknowledges that forward-looking statements involve material risks and uncertainties that could cause actual results or events to materially differ from expectations or predictions.
Corporate Developments: Discussion on corporate developments and financial results for the first quarter ended March 31, 2026.
Forward-Looking Statements: The company will be making forward-looking statements related to expectations or predictions of future events and market trends as well as estimated results or performance. These statements are based on current estimates and various assumptions, involving material risks and uncertainties that could cause actual results or events to materially differ.
The selected topic was not discussed during the call.
The earnings call indicates a positive sentiment due to a 15% revenue increase and improved gross margin from 60% to 65%. Despite a net loss, the reduction from $1.5 million to $1.2 million signals progress. The company's focus on high-growth segments and strategic initiatives further supports a positive outlook. However, the absence of guidance and increased operating expenses slightly temper enthusiasm. Overall, the financial performance and strategic focus suggest a positive stock price movement in the short term.
The earnings call presents a mixed picture. While there are some positive aspects such as increased gross margins and strategic focus areas, there are significant concerns. The company faces liquidity constraints, operating losses, and supply chain risks. The international market challenges and increased operating expenses add to the negative sentiment. Despite the optimistic guidance for 2026, the current financial health and operational challenges are likely to weigh on the stock price, leading to a negative sentiment prediction.
The earnings call reveals several challenges: a 6% revenue decline, reduced gross margins, increased operating expenses, and a higher operating loss. Despite some positive aspects like sequential revenue growth and a focus on U.S. market expansion, the termination of international operations and dependency on the U.S. market pose risks. The cash position is limited, and manufacturing transition risks exist. With no new partnerships or positive shareholder return plans discussed, the overall sentiment is negative, likely leading to a -2% to -8% stock price movement.
The earnings call presents a mixed picture. While there is growth in pediatrics and improved reimbursement for heart failure, the overall financial performance is concerning. Revenue declined by 21% due to a product back order, and margins fell significantly. The termination of the REVERSE-HF trial and increased net losses further add to the negative sentiment. Despite the resolution of the sterilization issue and potential in pediatrics, the financial challenges and operational risks outweigh the positives, leading to a negative outlook for the stock.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.